Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

  • John C. Byrd
  • , Kanti Rai
  • , Bercedis L. Peterson
  • , Frederick R. Appelbaum
  • , Vicki A. Morrison
  • , Jonathan E. Kolitz
  • , Lois Shepherd
  • , John D. Hines
  • , Charles A. Schiffer
  • , Richard A. Larson

Research output: Contribution to journalArticlepeer-review

383 Scopus citations

Fingerprint

Dive into the research topics of 'Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science